Mitogen-activated protein kinase kinase kinase 14 (NIK)

Mitogen-activated protein kinase kinase kinase 14 (NIK) is a serine/threonine kinase that is fundamental to the non-canonical NF-κB signaling pathway, regulating transcription of genes essential for B-cell survival, lymphoid tissue development, and immune responses[6][1][2][4][8]. NIK acts downstream of several tumor necrosis factor (TNF) family receptors and functions by phosphorylating IKKα, leading to proteolytic processing of NF-κB2/p100 to p52, which then translocates to the nucleus and activates gene expression[2][7][4]. NIK activity is tightly regulated by proteins such as TRAF2, TRAF3, and cIAPs, with excessive NIK activity implicated in tumorigenesis, autoimmunity, and inflammation[1][3]. As a validated therapeutic target, especially in cancer and autoimmune disease, NIK inhibition is under investigation, but no NIK-targeting drug has been clinically approved to date[3][8].

Other names

NF-κB-inducing kinaseMAP3K14Serine/threonine-protein kinase NIKNF-kappa-B-inducing kinaseHsNIK

Inhibition of NIK blocks non-canonical NF-κB pathway activation, reducing transcription of genes involved in cell survival, proliferation, and inflammation[3][1]. Inhibitor molecules typically compete for the ATP-binding site in the kinase domain[3][1].